Iovance Biotherapeutics Inc (IOVA)

[Structural_Biologist]

Largely agree with this. The 2027+ outlook is incredibly bright. To me this is a pseudo clinical commercial stage company with some income from 2L MM but it’s frontline MM, NSCLC, and endometrial that are the future. And most importantly IOV-5001. I have no optimism until lung data but I’m also not remotely worried here. I also didn’t over extend myself and so I don’t ever need the money I put here. And I’ll be slowly adding more as well.